Brexit - What's next for Life Sciences companies?

We hosted a webinar to learn more about the implications for the life sciences sector of the momentous decision that the UK has now made to leave the EU.

The Life sciences lawyers Elisabethann Wright, Stephen Bennett, Daniel Brook and Fabien Roy were joined by Peter Watts from our Constitutional Change Taskforce to discuss:

What effect will Brexit have for existing and future marketing authorisations for medicinal products?

How will medical device manufacturers be affected?

How does the decision affect past, current, and future clinical studies conducted in the UK? Are there related privacy implications?

Is there anything you should do immediately?

How can your businesses influence what happens next?


Back To Listing
Loading data